Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
about
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cellsT helper 17 cells promote cytotoxic T cell activation in tumor immunityAdoptive T cell therapy: Addressing challenges in cancer immunotherapyVaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencingRationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationCyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanomaBRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in miceNatural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity.Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccinationCombined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model.Therapeutic cancer vaccines: are we there yet?Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine modelAdjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer.Genetically modified T-cell therapy for osteosarcomaBroadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy.Toll-like receptors in tumor immunotherapy.Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses.Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in miceInterleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.Acute inflammation induces immunomodulatory effects on myeloid cells associated with anti-tumor responses in a tumor mouse model.The anticancer immune response: indispensable for therapeutic success?Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer.Harnessing the immune system to treat cancer.A comparison and critical analysis of preclinical anticancer vaccination strategies.Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells.Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen.Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer.Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivoTumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.Systemic therapy for advanced hepatocellular carcinoma: past, present, and future.
P2860
Q24530100-0302B176-74B4-43DE-B79B-B93A87F7964CQ24646584-61511B9C-2709-4762-B754-161DD345A43CQ24805804-34EEC7FF-5F61-4E0B-96A3-83239F132D6BQ26796314-FB425974-0DAA-48F0-A683-75287A2A4A39Q27334215-8BB3AF42-02E6-44E9-83F0-C96524FE31EBQ27686800-D784ADC5-DDFB-422D-B09B-A492C933F36EQ28068378-8CA3785E-6F88-4961-AAE6-2B9FC853175FQ33653210-91A24C17-F13A-42F6-AA6D-D8C82F30C1F3Q33806306-3C9EEC0A-844B-420E-90C9-9E5B34D3516AQ33996674-E98E393D-E9E5-44D0-8243-6507C8A07966Q34000832-971292A7-C957-4A38-8411-9FDB383CFBC1Q34667021-7A35F8D2-3327-429D-8E97-8ACF11FDAF97Q34732473-7D73531C-8E4A-41E7-931B-5595EC571792Q34759603-1A9EE536-1ED4-440F-8F86-0A785A8560ECQ34770289-60723CA3-E130-43F0-978E-EFDCF8BFA522Q34786691-EA9E8018-B475-4D14-9D57-D4E5D0ADCA79Q35223241-BF8FD502-D652-49DF-A9AC-4CB3BB08DF46Q35234948-70298CD6-881B-4DFB-BD1F-AA27AD4E7D52Q36037271-CF400F33-720A-4BC2-87E9-83D6BD3ABA5BQ36174218-AE78F1CB-FABC-4262-A7F1-CA4A261885ECQ36198232-C16D82FF-D9E4-46B4-A430-EC946591B327Q36239656-CD3FE086-E3AD-4980-8CCB-F30D69E3C64FQ36253608-E7480DD6-A961-4E46-9130-2EB465109734Q36333963-9BF9166E-620F-487D-A1E3-545E60592571Q36403509-308D4327-4A12-4931-AED9-27BD2C83B58BQ36456753-BC27FCE0-167C-43B4-BC83-949DB58F9B43Q36620354-95343786-4200-45D0-B851-84CF2387C8A0Q36677608-01B61D2F-CFD9-4DC7-BDEE-7992A652F6C6Q36694948-F4C94C4C-7938-43AC-89C3-5820A76B2F44Q36809755-123ED632-103D-454D-AC60-0FD572C362F7Q36951547-A2F8F4A9-DFC8-4C6F-89E4-F33B4189EF61Q37073501-657186C2-39AE-41B3-AB2B-884A70EA7102Q37090163-BEF7BF28-8C9C-47B8-9F96-5A3B5DCA4B80Q37178648-4D834E62-AC30-4766-8BFB-6921FDEEC55EQ37334596-E3FD2BD0-A564-4B7F-87C3-CE38DAE54156Q37346893-88C05BC6-148A-40B6-82B5-64279D3D7F29Q37386167-C41C3861-97AC-4E1A-84EF-5F01F3506E97Q37587713-C81F66C8-37D2-402C-AC06-AF3707D64779Q37690437-C29F27F7-FFC6-4920-AE9C-2CDC7C3BB21EQ37734197-7A705562-3B9B-4E8E-AF35-798C6889EACE
P2860
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Dendritic cells strongly boost ...... y transferred T cells in vivo.
@ast
Dendritic cells strongly boost ...... y transferred T cells in vivo.
@en
type
label
Dendritic cells strongly boost ...... y transferred T cells in vivo.
@ast
Dendritic cells strongly boost ...... y transferred T cells in vivo.
@en
prefLabel
Dendritic cells strongly boost ...... y transferred T cells in vivo.
@ast
Dendritic cells strongly boost ...... y transferred T cells in vivo.
@en
P2093
P2860
P1433
P1476
Dendritic cells strongly boost ...... ly transferred T cells in vivo
@en
P2093
Chiguang Feng
Grace J Kim
Gregory Lizée
Patrick Hwu
Steven E Finkelstein
Yanyan Lou
P2860
P304
P356
10.1158/0008-5472.CAN-04-1621
P407
P577
2004-09-01T00:00:00Z